VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease

NCT06874621 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease (AD)

Interventions

DRUG: VY7523
DRUG: Placebo Comparator

Sponsor

Voyager Therapeutics